Smart science to improve lives™

Best Supplier for COVID-19 Vaccine Development 2022

Croda, the company that uses smart science to improve lives, announces that it has been awarded winner of a prestigious award for its work in supporting vaccine development. The company has been awarded “Best Supplier for COVID-19 Vaccine Development” at the India Biologics & Vaccines Outstanding Industry Awards (BVOIA) 2022. 

The awards give recognition to exceptional biologics and vaccine experts, organisations and technologies that facilitate vaccine R&D and biologics manufacturing excellence at enhanced speed, reduced cost, and superior quality. 

This comes closely after Croda Pharma and Avanti Polar Lipids have presented at the World Vaccine Congress, Washington DC, and 12th Annual Vaccines World Summit, India, on their collaboration and work supporting vaccines globally. They have enabled a large number of Covid-19 vaccines through their diverse portfolio of innovative products including aluminium-based adjuvants and high-purity lipids for drug delivery systems.

The award was celebrated in person by the Croda teams. Christel Haugsted, Director, Supply Chain Management of Croda Denmark, said: 

“This is exactly what Croda is all about – working together and making a difference. A great achievement by our customers can only be possible with the help from dedicated commercial teams, working together directly with the manufacturing sites – in this case Croda Denmark. I am very proud to be part of this recognition, not only from the vaccine industry but from our customers. We can all be proud!”

Croda Pharma is continuously increasing its offering in innovative vaccine adjuvant systems, highest purity lipids and excipients in order to empower biologics delivery, and to support the supply of critical ingredients for vaccines. 

Most recently, Croda has been awarded a £15.9 million grant by the UK Government to expand its manufacturing facilities in Leek, Staffordshire, which will continue to enhance the development of high-purity lipids – essential for next generation nucleic acid drugs such as mRNA vaccines.





Established in 1925, Croda is the name behind sustainable, high-performance ingredients and technologies in some of the world’s most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere.


Croda is a FTSE 100 company with over 5,500 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart science to improve lives™.  As part of this Purpose, and with around two thirds of its organic raw materials already from bio-based sources, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030. 


About Croda Pharma


Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.